raw

The collaboration of US-based pharmaceutical company Charleston Laboratories and Japanese pharmaceutical company Daiichi Sankyo has received acceptance from the US Food and Drug Administration (FDA) for reviewing the New Drug Application (NDA) for CL-108.

CL-108 is a fixed-dose, immediate-release, bi-layered tablet that can be used to relieve moderate to severe pain while preventing or reducing the associated opioid-induced nausea and vomiting (OINV).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Opioids, substances that work on opioid receptors to create morphine-like effects, include opiates, which is an older term referring to drugs that are derived from opium, including morphine itself.

The two layers of the tablet comprises a rapid release layer containing 12.5mg of promethazine, and a second layer containing 7.5mg of hydrocodone and 325mg of acetaminophen.

"At Charleston Laboratories, a key part of our mission is to develop and commercialise products that provide patients with novel solutions for improving their pain management."

Charleston Laboratories president and CEO Paul Bosse said: "With this NDA acceptance, patients are one step closer to being able to have an option for relieving pain while also preventing or minimising the nausea and vomiting side effects of opioid treatment.

See Also:

    "At Charleston Laboratories, a key part of our mission is to develop and commercialise products that provide patients with novel solutions for improving their pain management."

    How well do you really know your competitors?

    Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

    Company Profile – free sample

    Thank you!

    Your download email will arrive shortly

    Not ready to buy yet? Download a free sample

    We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

    By GlobalData
    Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

    The NDA for CL-108 is supported by two major randomised, double-blind, placebo-controlled and active-controlled Phase III clinical studies.

    The first study involves an oral surgery (molar removal), while the second involves post bunionectomy surgery (removal of bunions from the foot), as well as by an additional Phase III open-label, actual use safety study in patients with moderate-to-severe acute pain or flares that are associated with osteoarthritis of the knee or hip.

    Image: A sample of raw opium. Photo: courtesy of Erik Fenderson.